Clinical trials: Cardiovascular Condition
Venous Leg Ulcer
Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers
A Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of GrafixPL for the Treatment of Chronic VLUs
- Trial name
- NCT03629236
- Testing
- GrafixPL, Control
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Osiris Therapeutics
Diabetic Retinopathy
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
The main objectives of this observational study were to describe outcomes, monitoring and treatment patterns of patients with diabetic macular edema in routine clinical practice who are either treatment naïve patients or…
- Trial name
- APOLLON (NCT02924311)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- France
- Volunteers
- 402 people
- Sponsor
- Bayer
Arrhythmias, Cardiac
EASYER (EpiAccess SYstem Registry) A Post Market Observational Registry
The objective of the Registry is to provide post market clinical outcome and potential health economics data and confirm the continued safety of the EpiAccess system.
- Trial name
- EASYER (NCT02481102)
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- EpiEP, Inc.
Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT)
Evaluation of Soluble Fibrin in Thrombosis Exclusion
The purpose of the study is to evaluate the performances of Soluble Fibrin assay for exclusion of Pulmonary Embolism and Deep Venous Thrombosis.
- Trial name
- FSET (NCT02523937)
- Testing
- Soluble Fibrin
- Where
- France
- Volunteers
- 863 people
- Sponsor
- Diagnostica Stago R&D
Chronic Venous Insufficiency
EU Post Market Clinical Follow-Up Study of the Venclose System for Saphenous Vein Incompetence
This is a prospective, non-randomized study in which patients who meet eligibility criteria and consent to participate will undergo a minimally invasive procedure using radiofrequency (RF) energy for ablation of the great…
- Trial name
- NCT04236245
- Testing
- Venclose RF System
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Venclose, Inc.
Atherosclerosis Cardiovascular Disease, ASCVD
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD.
- Conditions
- Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
- Trial name
- NCT07303777
- Testing
- ABP-745 Dose A, ABP-745 Dose B, ABP-745 Dose C
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 200 people
- Sponsor
- Atom Therapeutics Co., Ltd
Peripheral Vascular Disease
Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System
The objective of this clinical investigation is to evaluate the safety and efficacy of the Minnow Medical GRST™ Peripheral Catheter System in the treatment of de novo lesions in the superficial femoral artery (SFA) or the…
- Trial name
- NCT00881257
- Testing
- GRST Peripheral Catheter System
- Where
- 2 sites in Germany
- Volunteers
- 78 people
- Sponsor
- Vessix Vascular, Inc
Stroke, Ischemia
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
The purpose of this study is to evaluate the safety and tolerability of 42037788 (CNTO 0007) in patients who have suffered a stroke.
- Conditions
- Stroke, Ischemia, Infarction
- Trial name
- NCT01273467
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Janssen Research & Development, LLC
Ischemic Stroke
The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)
This is a multicenter study that will be conducted at approximately 20 centers. BQ 2.0 is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned…
- Trial name
- BQ5 (NCT05044507)
- Testing
- BQ 2.0
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- BrainQ Technologies Ltd.
Fabry Disease
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
The aim of this study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease.
- Trial name
- RISE (NCT05710692)
- Testing
- PRX-102 1 mg/kg every 2 weeks, PRX-102 2 mg/kg every 4 weeks
- Where
- 10 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Hypertension, Hyperlipidemias
To Evaluate Safety and Effectiveness of RovatitanTab.
To evaluate the safety and effectiveness of a fixed-dose combination containing valsartan and rosuvastatin (Rovatitan® Tablet) in patient with hypertension and hypercholesterolemia
- Trial name
- NCT04398771
- Testing
- Rosuvastatin/Valsartan
- Volunteers
- 1,000 people
- Sponsor
- LG Chem
Hematologic Cancer
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of…
- Trial name
- NCT05753501
- Testing
- ABBV-101, Venetoclax
- Where
- 51 sites in United States, Canada and 7 more
- Volunteers
- 135 people
- Sponsor
- AbbVie
Stroke, Hemiparesis After Stroke
Prospective Real-World Evidence Study of the IpsiHand® System in Adult Stroke Survivors
This study focuses on monitoring real-world customers who have been prescribed the IpsiHand® as part of their rehabilitation post-stroke.
- Conditions
- Stroke, Hemiparesis After Stroke, Brain Computer Interface
- Trial name
- NCT07147881
- Testing
- IpsiHand
- Volunteers
- 100 people
- Sponsor
- Neurolutions, Inc.
Down Syndrome, Edwards Syndrome
Non-Invasive Screening for Fetal Aneuploidy
The purpose of this study is to detect whole chromosome abnormalities in maternal blood.
- Trial name
- NCT02317965
- Testing
- Maternal Blood Draw
- Where
- 10 sites in United States
- Volunteers
- 340 people
- Sponsor
- Progenity, Inc.
Blood Loss, Surgical
HemoSonics - UTMB Cardiac Surgery Study
This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the Quantra QPlus Cartridge in patients undergoing cardiac surgery utilizing cardiopulmonary bypass, including the…
- Trial name
- NCT03988465
- Testing
- Quantra System
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- HemoSonics LLC
Pulmonary Arterial Hypertension
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus background PAH therapy) on…
- Trial name
- HYPERION (NCT04811092)
- Testing
- Sotatercept
- Where
- 152 sites in United States, Argentina and 25 more
- Volunteers
- 321 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Essential Hypertension
Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.
- Trial name
- NCT00856271
- Testing
- olmesartan medoxomil, losartan potassium
- Where
- 5 sites in China
- Volunteers
- 287 people
- Sponsor
- Daiichi Sankyo
Hypertension
ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
To compare the antihypertensive efficacy of the combination irbesartan/hydrochlorothiazide (HCTZ) using either a usual or an active elective titration regimen.
- Trial name
- ACTUAL (NCT00708344)
- Testing
- Irbesartan - Hydrochlorothiazide
- Where
- 16 sites in Algeria, Argentina and 14 more
- Volunteers
- 832 people
- Sponsor
- Sanofi
Hereditary Angioedema
Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema
The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. Lanadelumab, also known as TAK-743, is a medicine to help prevent hereditary angioedema attacks.
- Trial name
- NCT04687137
- Testing
- TAK-743 300 mg
- Where
- 9 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Takeda
Pressure Ulcer, Leg Ulcer
Evaluation Of An Advanced Borderless Dressing
This study will gather preliminary clinical, health economic, and safety data on the treatment of chronic wounds with the ALLEVYN Life Non-Bordered dressing compared to standard of care treatment when used on a wound.
- Conditions
- Pressure Ulcer, Leg Ulcer, Diabetic Foot Ulcer
- Trial name
- NCT03146845
- Testing
- ALLEVYN Life Non-Bordered, Standard Care
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Smith & Nephew, Inc.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.